
In the third episode, Dr Nadia Harbeck and Professor Alessandra Gennari turn their attention to a discussion of the completed clinical trials for CDK4/6 inhibitors in early breast cancer, namely PALLAS and PENELOPE-B for palbociclib and monarchE for abemaciclib. The divergent results for palbociclib and abemaciclib were unexpected, particularly as both proved effective in the metastatic setting and are now standard therapy for this indication. Dr Harbeck and Professor Gennari share their views on the possible reasons for the different outcomes with palbociclib and abemaciclib in early breast cancer.
Sep 22, 2022
15 min

Dr Nadia Harbeck and Professor Alessandra Gennari delve deeper into the RxPonder trial to explore the design and primary outcomes of the trial. Dr Harbeck and Professor Gennari engage in an insightful discussion of how RxPonder validated the use of the 21-gene expression assay as a tool to identify patients who could be spared chemotherapy.
Sep 22, 2022
9 min

In this first episode, Dr Nadia Harbeck and Professor Alessandra Gennari discuss ground-breaking trials, including the TailorX and RxPonder trials, that validated the use of gene expression assays to inform therapy decisions for patients with early breast cancer. Dr Harbeck also describes the ADAPT series, which combines gene expression assays with endocrine response to individualise therapy.
Sep 22, 2022
14 min